The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
Second interchangeable biosimilar product approved by agency
U.S. FDA to decide whether to authorize a booster dose in the coming days
First anticipated spinout from the alliance, Circle Therapeutics, to develop novel muscle stem cell therapies for a variety of skeletal muscle disorders
The interim analysis showed that the MVC-COV1901 vaccine has a good safety profile and elicits promising neutralising antibody titres
Equity raise to finance growth and investments in the biological space
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
This expansion will support the global operations network and help meet global demand for mammalian development services that support Lonza’s manufacturing sites
An amount of Rs. 70.9 crore has been earmarked for funding capital expenditure for the proposed expansion
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
Subscribe To Our Newsletter & Stay Updated
